Findings

What do systematic reviews say?

637 questions · 714 findings · 96 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 98 · 13.7%GRADE not reported 191 · 26.8%Very low 157 · 22%Low 161 · 22.5%Moderate 87 · 12.2%High 20 · 2.8%

High‐dose vs low‐dose colchicine

Withdrawals due to adverse events · acute gout

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 126 participants
GRADE not reported

High‐dose vs low‐dose rFVIIa

Annualized joint Bleeding Rate (AjBR) · adults and children with hemophilia A or B with inhibitors

The review found no eligible studies for this question.

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose rFVIIa

Quality of life · adults and children with hemophilia A or B with inhibitors

The review found no eligible studies for this question.

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose rFVIIa

Safety of bypassing agents · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 46 participants
Moderate

High‐dose vs low‐dose rFVIIa

Number of total bleeds per year or bleeding frequency · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Moderate

High‐dose vs low‐dose rFVIIa

Annualised bleeding rate · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
GRADE not reported

High‐dose vs low‐dose rFVIIa

Target joint bleeding rate · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Moderate

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Low

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Economic outcomes · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Higher‐dose vs lower‐dose nicotine patch

Smoking cessation · people who smoke

Higher‐dose showed no clear difference in smoking cessation ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (moderate certainty).

3 findings from 1 review

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.09 [0.93, 1.29]
5 studies · 1655 participants
Moderate
Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.19 [1, 1.41]
3 studies · 3446 participants
Moderate
Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.48 [1.06, 2.08]
1 study · 537 participants
Moderate

Higher‐dose vs lower‐dose nicotine patch

SAEs · people who smoke

Higher‐dose showed no clear difference in overall SAEs ‐ 42/44 mg versus 21/22 mg (24 hr patches) compared with lower‐dose nicotine patch (low certainty).

2 findings from 1 review

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
RR 5.01 [0.87, 28.82]
2 studies · 1023 participants
Low
Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 537 participants
Low

Higher‐dose vs lower‐dose nicotine patch

Treatment withdrawal · people who smoke

Higher‐dose may leads to higher treatment withdrawals ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).

1 finding from 1 review

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
RR 4.99 [1.6, 15.5]
2 studies · 554 participants
Low

Higher‐dose vs lower‐dose nicotine patch

Treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) · people who smoke

Higher‐dose showed no clear difference in treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).

1 finding from 1 review

Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation 2023 · Cochrane Headline outcomes only
RR 0.77 [0.36, 1.64]
1 study · 537 participants
Low

Higher‐dose vs lower dose

Deaths · patients with acute organophosphate pesticide poisoning

It is very uncertain whether higher dose changes deaths compared with lower dose (very low certainty).

1 finding from 1 review

Oximes for acute organophosphate pesticide poisoning 2011 · Cochrane Headline outcomes only
OR 0.38 [0.1, 1.47]
4 studies · 479 participants
Very low

Higher‐dose vs lower dose

Intermediate syndrome · patients with acute organophosphate pesticide poisoning

It is very uncertain whether higher dose changes intermediate syndrome compared with lower dose (very low certainty).

1 finding from 1 review

Oximes for acute organophosphate pesticide poisoning 2011 · Cochrane Headline outcomes only
OR 0.94 [0.24, 3.62]
3 studies · 283 participants
Very low